Super news they are progressing XP quickly.
The following link gives what I think is a really nice summary of the current strategic situation - nicely poised for an acceleration of development.
It also has a very interesting detail:
"TWO more indications will be announced in the coming weeks, he said."
Surely that has to tie in with the mid October strategic review they've been talking about. Exciting times.
https://www.bioworld.com/articles/497724-australias-clinuvel-expands-rd-presence-as-it-builds-out-pipeline-for-dna-repair
Ann: First patient dosed in SCENESSE DNA Repair Program, page-4
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.96 |
Change
-0.210(1.48%) |
Mkt cap ! $698.8M | |||
| Open | High | Low | Value | Volume |
| $14.10 | $14.11 | $13.90 | $1.044M | 74.52K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 1049 | $13.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.07 | 359 | 1 |
View Market Depth
| Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
| CUV (ASX) Chart |